Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Sponsor: Ipsen
Summary
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Official title: Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2025-04-22
Completion Date
2029-11
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Locations (10)
Children's Hospital Los Angeles
Los Angeles, California, United States
UCSF Benioff Children's Hospital
San Francisco, California, United States
The Children's Mercy Hospital
Kansas City, Missouri, United States
SSM Health Cardinal Glennon Children's Hospital
St Louis, Missouri, United States
NYU Langone - NYU Grossman School of Medicine
New York, New York, United States
Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
New York, New York, United States
Le Bonheur Children's Hospital
Memphis, Tennessee, United States
Children's Medical Center Of Dallas
Dallas, Texas, United States
Proactive El Paso,LLC
El Paso, Texas, United States
Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
Salt Lake City, Utah, United States